WSL
ABUS icon

Western Standard LLC’s Arbutus Biopharma ABUS Stock Holding History

Western Standard LLC’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Buy
542,787
+21,200
+4% +$93.1K 0.88% 21
2026
Q1 		$2.35M Buy
521,587
+13,734
+3% +$60.1K 1.23% 20
2025
Q4 		$2.44M Hold
507,853
– – 1.13% 17
2025
Q3 		$2.31M Buy
+507,853
New +$1.87M 0.68% 21

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Western Standard LLC's ABUS Position: Q2 2026 in Review

Western Standard LLC increased its Arbutus Biopharma (ABUS) stake by 4.1% in Q2 2026, buying an estimated $93.1K and bringing the position to 542,787 shares worth $2.61M. The position accounts for 0.88% of the portfolio, ranked #21.

Western Standard LLC first reported a position in ABUS in Q3 2025 and has held it in 4 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Western Standard LLC held 542,787 shares of Arbutus Biopharma worth $2.61M as of Q2 2026.
  • Western Standard LLC bought 21,200 Arbutus Biopharma shares in Q2 2026, an estimated $93.1K.
  • Arbutus Biopharma made up 0.88% of Western Standard LLC's portfolio in Q2 2026, its #21 holding.
  • Western Standard LLC first reported a position in Arbutus Biopharma in Q3 2025 and has held it in 4 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Western Standard LLC's 13F filing for Q2 2026, filed 10 Aug 2026.